Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

bortezomib

Home/Tag:bortezomib
10 11, 2013

New study proves acupuncture helps control Velcade induced PN

Tags: , , , , |7 Comments

Suffering from uncomfortable or painful peripheral neuropathy (PN) caused by using Velcade (bortezomib)?  Very little research has been done on drug induced PN; it's mostly focused on diabetic neuropathy, which encompasses a much larger patient subset.  Good news!  Check out excerpts from a helpful article on Medscape's website on the subject: Acupuncture Reduces Neuropathy Associated

15 06, 2013

Consolidation Therapy? Myeloma Cinderella clues-us-in

Tags: , , , , , |12 Comments

After stepping-back and taking some time to establish her own rockin' blog, Myeloma Cinderella is back.  What a treat!  Back to back columns from my two favorite contributors. WARNING: You are leaving my acronym-free zone Myeloma Cinderella is big on acronyms--the alphabet soup I try to avoid--and often uses terms I don't normally use.  I

12 03, 2013

BREAKING NEWS: HIV drug may help Velcade and Kyprolis work better

Tags: , , , , , , , |5 Comments

  I haven't had a chance to review the data yet, but Danny Parker forwarded me these links moments ago: Pat, This just off the medical press and called out by Dr. Robert Orlowski. Oral protease inhibitor, Nelfinavir, used against HIV, enhances the activity of Bortezomib against myeloma. Even more important, it appears to overcome

15 02, 2013

New study pinpoints Velcade as drug of choice for high risk myeloma patients

Tags: , , , , , , , , |11 Comments

Our good friend and nutritional columnist, Danny Parker, is excited about a new study released last week in the Journal of the American Society of Hematology:  Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Danny is considered a high risk patient, so I understand why this comprehensive study

25 08, 2012

Alpha Lipoic Acid not good for myeloma patients

Tags: , , , , , |13 Comments

Alpha lipoic acid is one of the best--if not the best--anti-neuropathy supplements available.  Velcade (bortezomib) causes peripheral neuropathy (PN) in most patients that use it. So understandably, many cancer centers that treat multiple myeloma are recommending patients take alpha lipoic acid (ALA) to help minimize Velcade induced PN. But apparently, alpha lipoic acid shouldn't be

23 06, 2012

Exciting new research helps prove timing can be everything!

Tags: , , , , , |2 Comments

Have you read yesterday's post?  Think the timing of when and how you use a drug isn't important?  Check-out this research development which relies on timing to help break-down myeloma cells: Stopping and Starting Cancer Cell Cycle Weakens and Defeats Multiple Myeloma ScienceDaily (June 21, 2012) — Weill Cornell Medical College researchers have devised an

9 04, 2012

The crazy world of “myeloma research speak”

Tags: , , , , , , , , , , , , , |0 Comments

Most of you probably know that I have been working on several new books about multiple myeloma.  My third book, New Myeloma Therapies from a Patient's Perspective, will be published and available by the end of this month.  Researching this book reminded me about how difficult it can be to understand "myeloma research speak."  It

9 06, 2011

ASCO Odds/Ends And Clinical Study Links

Tags: , , , , , , , , , , |0 Comments

A few more quick notes from ASCO before the first of a long running series about ways to improve peripheral neuropathy (PN) starts later today: Secondary Cancer Risk From Using Revlimid: Based on the results of this retrospective analysis, Dr. Palumbo concluded that Revlimid ,when used with melphalan, increases the rate of secondary cancers.  The

8 05, 2011

Early Results Show Velcade Is Also Effective As A Maintenance Therapy Agent, Post SCT

Tags: , , , , , , |2 Comments

If you have been following news from this week's International Myeloma Workshop in Paris, you couldn't help but notice how the big news centered around a Revlimid maintenance therapy.  The focus wasn't on how Revlimd maintenance extended progression free survival.  The excitement was generated by statistics which showed an 8% increase in patient median life expectancy.Here

9 03, 2011

Thalomid Or Velcade Both Work At Least 50% Of The Time In Patients Facing First Relapse

Tags: , , , , , , , , |3 Comments

According to a new Czech study, posted earlier this month on Pub Med.gov, it doesn't matter whether you pick thalidomide (Thalomid) or bortezomib (Velcade) for treatment following first relapse.  Apparently both work about one half of the time.Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.Krejci M, Gregora E, Straub J,

16 12, 2010

Summary of Three Bortezomib (Velcade) Studies In Elderly Patients By Internal Medical News

Tags: , , , , |0 Comments

It is always interesting to see how the general medical community views multiple myeloma/ASH related news.  Here is an article from the well respected Internal Medical News about three Millennium Pharmaceutical studies featuring bortezomib (Velcade) at ASH:Bortezomib-Based Regimens Help Older Patients With Multiple Myeloma By: NEIL OSTERWEIL, Internal Medicine News Digital Network - 12/15/10 Major

12 11, 2010

Specifics About Millennium Sponsored Studies To Be Featured At ASH

Tags: , , , , , |0 Comments

Yesterday's article, Pre-American Society Of Hematology (ASH) News Starting To Break, featured the first part of Millennium Pharmaceutical's Curtainraiser ASH Preview Press Release.Here is a preview of major studies involving Velcade which will be presented at ASH:Multiple MyelomaHOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and

17 10, 2010

Some Good News About Vorinostat: Oncologists Can Use It "Off Label" In Multiple Myeloma Patients

Tags: , , , , , |0 Comments

I would like to take this opportunity to once again thank Dr. Eric Rubin, Vice President of Merck Oncology, for taking the time to update us on vorinostat's projected timeline.You may have noticed quite a bit of hedging and "drug company speak" toward the end of our interview.  I want to point out that Dr. Rubin wasn't intentionally

7 10, 2010

Spanish Study Finds Velcade Very Effective For Elderly Multiple Myeloma Patients

Tags: , , |0 Comments

Results of a randomized clinical trial in Spain shows that reduced intensity, bortezomib-based (Velcade) induction therapy, followed by bortezomib-based maintenance therapy, results in a favorable toxicity profile and high efficacy among older patients.  Go to OncologySTATS' site to read the study.I saw results from a similar study in the U.S. at ASCO in Chicago this past

9 09, 2010

Early Research Study Using New Oral Proteasome Inhibitor Shows Promise

Tags: , , , |0 Comments

Velcade is currently the only FDA approved proteasome inhibitor. Here is an encouraging research study using a new oral proteasome inhibitor ONX 0912, which was submitted to the internationally recocognized medical journal, Blood, April 2, 2010; accepted August 8, 2010. Here is a copy of the study abstract:A novel orally active proteasome inhibitor ONX 0912

27 08, 2010

Restrictive New Rules May Limit Access To Velcade For Some Newly Diagnosed Multiple Myeloma Patients In The UK

Tags: , , |2 Comments

Here is an English press release from the company which distributes Velcade in the UK.  Looks like the British may be headed in the wrong direction here:NICE proposes to restrict access to Velcade® (bortezomib)in newly diagnosed multiple myeloma patientsJanssen-Cilag to challenge NICE recommendationJanssen-Cilag, High Wycombe, 26 August 2010 – Janssen-Cilag is disappointed that recommendations from

13 08, 2010

Velcade Plus Dex Improves Survival Of Multiple Myeloma Patients With 4/14 Chromosome Deletion When Used During Induction

Tags: , , , , |1 Comment

OncologyStat.com reports there is some good news for multiple myeloma patients with chromosomal abnormalities:Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)TAKE-HOME MESSAGEIn this large, retrospective analysis of patients with newly diagnosed multiple myeloma, bortezomib-based induction therapy before high-dose melphalan and stem cell transplantation was associated

13 07, 2010

More About When To Get A Stem Cell Transplant (SCT) & Success Of RVD Drug Combo

Tags: , , , , , , , , , |0 Comments

Here is the body of the article about multiple myeloma related research studies I started to post yesterday,  Is It Time to Abandon Up-Front Transplantation in Multiple Myeloma? Elsevier Global Medical News, written by P. Wendling on the medical professionals only site, Oncology STAT: He (Dr. Jean-Luc Harousseau) cited data from several trials, including the pivotal phase